IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (1415)	1/12/1998 4:02:00 PM
From: Roudy	Read Replies (1) of 1762

I spoke with IDEC investor relations today. The XOMA deal was between Genetech and XOMA with no cost or reflection on IDEC. The deal did cover the entire royalty stream as I understood it. Rituxan sale orders are coming in daily with an indication that possibly one large network healthcare provider is purchasing. The sales force is showing a very strong response and expectations for Rituxan. IDEC has a sales force of 25 and Genetech has 40. The Dec. ending quarter will be following Genetech's qtrly report expected in the third week of Jan. We shouldn't expect to much out of this quarter since Rituxan only started shipping in mid Dec. and start up expenses will be in this quarter. We could also expect to hear some results on Phase II of IDEC-151 (second generation of CE9.1) by the end of this month. Anybody else hearing anything on Rituxan?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next